Historique
Rapport
Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs
(Rapport sur l'évaluation du risque lié à la consommation de TMA-2 dans le cadre de l'action commune sur les nouvelles drogues de synthèse)
Année
2004
Page(s) :
74 p.
Langue(s) :
Anglais
Éditeur(s) :
Lisbon : OEDT / EMCDDA
;
Luxembourg : Office for Official Publications of the European Communities
Collection :
Risk assessments, n°7
ISBN :
978-92-9168-186-2
Refs biblio. :
38
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PRO (Produits, mode d'action, méthode de dépistage / Substances, action mode, screening methods)
Thésaurus géographique
UNION EUROPEENNE
Thésaurus mots-clés
DROGUES DE SYNTHESE
;
TMA
;
TOXICITE
;
PHARMACOLOGIE
;
EFFET SECONDAIRE
;
EVALUATION
;
LEGISLATION
;
TRAITE INTERNATIONAL
;
SURVEILLANCE EPIDEMIOLOGIQUE
;
FACTEUR DE RISQUE
;
SAISIE
Note de contenu :
CONTENTS:
Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs
Europol–EMCDDA progress report on TMA-2
Review of the pharmacotoxicological data on TMA-2
Sociological and criminological evidence and public health risks
Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs
Europol–EMCDDA progress report on TMA-2
Review of the pharmacotoxicological data on TMA-2
Sociological and criminological evidence and public health risks
Résumé :
ENGLISH :
Since the adoption by the Council in June 1997 of the joint action on the information exchange, risk assessment and control of new synthetic drugs, TMA-2 (2,4,5-trimethoxyamphetamine) is the ninth substance to be subjected to risk assessment. Synthesised in 1947, TMA-2 is one of the numerous "new synthetic drugs" with no legitimate therapeutic use that are described in Shulgins Pikhal (Shulgin and Shulgin, 1991). TMA-2 can be produced from the active agent asarone (2,4,5- trimethoxyphenyl-1-propenylbenzene), which is extracted from the rhizome of the plant Acorus calamus. The precursor asarone (2,4,5-trimethoxyphenyl-1- propenylbenzene) is widely used as an active principle in food flavourings. TMA-2 has the structural characteristics of amphetamines, which are associated with hallucinogenic and stimulant actions. It is an analogue that is very close to TMA (3,4,5-trimethoxyamphetamine) but is 10 times more potent (20 mg of TMA-2 induces the same hallucinogenic effects as 200 mg of TMA). Therefore it carries potential risks common to TMA and other hallucinogenic substances (e.g. DOM, DOB) already classified in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. The specific scientific risk assessment of TMA-2 has been extremely difficult, due to the lack of peer-reviewed scientific data. There are, however, some limited data from studies carried out in the 1970s and 1980s. An overview of the pharmacology, toxicology, clinical experience and individual health and psychological risks of TMA-2 use was compiled by Michel Mallaret of the Centre dévaluation et dinformation sur la pharmacodépendance, Centre hospitalier universitaire, Grenoble. Moreover, Mallaret performed an original study on the toxic effects of TMA-2 in rats. This overview was further extended by a review, completed by the EMCDDA and Europol, of the pharmacotoxicological, sociological and criminological information available on TMA-2. Information based on analogy to related compounds, such as TMA, was also utilised for this assessment. (Extract of the publication)
Since the adoption by the Council in June 1997 of the joint action on the information exchange, risk assessment and control of new synthetic drugs, TMA-2 (2,4,5-trimethoxyamphetamine) is the ninth substance to be subjected to risk assessment. Synthesised in 1947, TMA-2 is one of the numerous "new synthetic drugs" with no legitimate therapeutic use that are described in Shulgins Pikhal (Shulgin and Shulgin, 1991). TMA-2 can be produced from the active agent asarone (2,4,5- trimethoxyphenyl-1-propenylbenzene), which is extracted from the rhizome of the plant Acorus calamus. The precursor asarone (2,4,5-trimethoxyphenyl-1- propenylbenzene) is widely used as an active principle in food flavourings. TMA-2 has the structural characteristics of amphetamines, which are associated with hallucinogenic and stimulant actions. It is an analogue that is very close to TMA (3,4,5-trimethoxyamphetamine) but is 10 times more potent (20 mg of TMA-2 induces the same hallucinogenic effects as 200 mg of TMA). Therefore it carries potential risks common to TMA and other hallucinogenic substances (e.g. DOM, DOB) already classified in Schedule I of the 1971 United Nations Convention on Psychotropic Substances. The specific scientific risk assessment of TMA-2 has been extremely difficult, due to the lack of peer-reviewed scientific data. There are, however, some limited data from studies carried out in the 1970s and 1980s. An overview of the pharmacology, toxicology, clinical experience and individual health and psychological risks of TMA-2 use was compiled by Michel Mallaret of the Centre dévaluation et dinformation sur la pharmacodépendance, Centre hospitalier universitaire, Grenoble. Moreover, Mallaret performed an original study on the toxic effects of TMA-2 in rats. This overview was further extended by a review, completed by the EMCDDA and Europol, of the pharmacotoxicological, sociological and criminological information available on TMA-2. Information based on analogy to related compounds, such as TMA, was also utilised for this assessment. (Extract of the publication)
Affiliation :
Portugal